Ian Robert Silverman
General Counsel presso CONCERT PHARMACEUTICALS, INC.
Provenienza dei contatti di primo grado di Ian Robert Silverman
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Private Company | Pharmaceuticals: Major | 33 | |
Revere Pharmaceuticals, Inc.
 Revere Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Revere Pharmaceuticals, Inc. provides pharmaceuticals services. It offers oncology and drug development. The company was founded by Robert Ian Silverman in 2016 and is headquartered in Arlington, MA.
2
| Holding Company | Pharmaceuticals: Major | 2 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Ian Robert Silverman tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| ABBOTT LABORATORIES | Medical Specialties | Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| VERTEX PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| CITIGROUP INC. | Major Banks | Corporate Officer/Principal Corporate Officer/Principal | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Director of Finance/CFO | |
Faraday Pharmaceuticals, Inc. (Washington)
 Faraday Pharmaceuticals, Inc. (Washington) Drugstore ChainsRetail Trade Faraday Pharmaceuticals, Inc. develops small molecule drugs for the treatment of central nervous system disorders and cardiovascular diseases. The company was founded in 2001 and is headquartered in Seattle, WA. | Drugstore Chains | Corporate Officer/Principal Corporate Officer/Principal | |
| ALEXZA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Operating Officer Chief Tech/Sci/R&D Officer | |
| TETRAPHASE PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| RAPID MICRO BIOSYSTEMS, INC. | Industrial Machinery | Director/Board Member | |
Anchor Therapeutics, Inc.
 Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
GSK Equity Investments Ltd.
 GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Investment Managers | President | |
| Dartmouth College | College/University | Doctorate Degree Undergraduate Degree Undergraduate Degree | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Doctorate Degree | |
| IMUGENE LIMITED | Biotechnology | Director/Board Member | |
Affymax Research Institute
 Affymax Research Institute Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Affymax Research Institute is a private company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
| Boston University | College/University | Graduate Degree Undergraduate Degree | |
GPC Biotech, Inc.
 GPC Biotech, Inc. Drugstore ChainsRetail Trade GPC Biotech, Inc. discovers and develops anticancer drugs through discovery technologies and development approaches. It is a mechanism-based drug discovery and development company focused on treatments for cancer and fungal infections. The company is a wholly owned subsidiary of GPC Biotech AG. GPC Biotech was founded in 1992 and is located in Waltham, MA. | Drugstore Chains | Corporate Officer/Principal Corporate Officer/Principal | |
| XENOPORT, INC. | Pharmaceuticals: Major | Chairman Director/Board Member Chief Executive Officer | |
| Babson College | College/University | Undergraduate Degree Masters Business Admin | |
| Massachusetts Institute of Technology | College/University | Graduate Degree Doctorate Degree | |
| Bucknell University | College/University | Undergraduate Degree | |
| Rutgers State University of New Jersey | College/University | Doctorate Degree | |
Northeastern University
 Northeastern University Other Consumer ServicesConsumer Services Founded in 1898, Northeastern University is a private research university located in the heart of Boston. Northeastern teaches worldwide experiential learning, urban engagement, and interdisciplinary research that meets global and societal needs. The University offers a range of undergraduate and graduate programs leading to degrees through the doctorate in nine colleges and schools. | College/University | Undergraduate Degree Undergraduate Degree | |
| ENANTA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
SelectX Pharmaceuticals, Inc.
 SelectX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SelectX Pharmaceuticals, Inc. engages in the discovery and development of aminoglycoside therapeutics for unmet medical needs. Its advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs); SXP2523 possesses broad spectrum coverage with potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus. The company was founded by Michael G. Chaparian and Charles R. Cantor in 2002 and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| Universität Konstanz | College/University | Doctorate Degree | |
TVM Capital Corp.
 TVM Capital Corp. Investment ManagersFinance TVM Capital Corp (TVM Capital) is a venture capital subsidary of TVM Capital GmbH founded in 1986. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor | |
| Harvard Medical School | College/University | Doctorate Degree Doctorate Degree | |
Max-Planck-Innovation GmbH
 Max-Planck-Innovation GmbH Miscellaneous Commercial ServicesCommercial Services Max-Planck-Innovation GmbH provides technology transfer from the research institutes. It offers technology transfer, patenting, licensing and start-up solutions. The company was founded in 1971 and is headquartered in Munich, Germany. | Miscellaneous Commercial Services | Director/Board Member | |
Cambridge Medical & Rehabilitation Centre
 Cambridge Medical & Rehabilitation Centre Hospital/Nursing ManagementHealth Services Cambridge Medical & Rehabilitation Centre provides healthcare, rehab, and admission services. It provides individualized non-acute long-term care and therapies to patients who need post-hospital medical and rehabilitative treatment at intermediate or intensive levels of care. The firm also offers individualized non-acute medical, nursing, rehabilitation and social services to treat and support each of its residents, including a range of rehabilitation programs for residents who recover from an injury or illness. The company was founded in 2012 and is headquartered in Abu Dhabi, United Arab Emirates. | Hospital/Nursing Management | Chairman | |
Biohealth Innovation, Inc.
 Biohealth Innovation, Inc. Financial ConglomeratesFinance Biohealth Innovation, Inc. sources and evaluates market-relevant bioheath intellectual properties, connects the IP with funding, and assists businesses in marketing and growth. It is a regional innovation intermediary that accelerates and facilitates technology transfer and commercialization of market-relevant research in federal labs, universities, and biohealth companies in the Region. The company was founded in 2011 and is headquartered in Rockville, MD. | Financial Conglomerates | Director/Board Member | |
Action Potential Venture Capital
 Action Potential Venture Capital Investment ManagersFinance Action Potential Venture Capital (Action Potential Venture) is a venture capital subsidiary of GlaxoSmithKline Plc founded in 2013. The firm is headquartered in London, United Kingdom. | Investment Managers | Director/Board Member | |
ZappRx, Inc.
 ZappRx, Inc. Miscellaneous Commercial ServicesCommercial Services ZappRx, Inc. develops prescription and prior authorization platform services. It provides healthcare providers, specialty pharmacies, biopharmacies, and security standards solutions. The company was founded by Zoe Barry in 2012 and is headquartered in Boston, MA. | Miscellaneous Commercial Services | Director/Board Member | |
Gladius Pharmaceuticals Corp.
 Gladius Pharmaceuticals Corp. BiotechnologyHealth Technology Gladius Pharmaceuticals Corp. operates as a biotechnology firm. The company is headquartered in Wilmington, DE. | Biotechnology | Director/Board Member | |
| DECIBEL THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Apollo Ventures Holding GmbH
 Apollo Ventures Holding GmbH Investment ManagersFinance Apollo Ventures Holding GmbH (Apollo Health Ventures) is an Independent Venture Capital firm founded in 2016 by Nils Regge and Alexandra Bause. The firm is headquartered in Hamburg. | Investment Managers | Private Equity Investor | |
Palleon Pharma, Inc.
 Palleon Pharma, Inc. BiotechnologyHealth Technology Palleon Pharma, Inc. operates as a biotechnology company. The company is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
Obsidian Therapeutics, Inc.
 Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Biotechnology | Director of Finance/CFO | |
Aeovian Pharmaceuticals, Inc.
 Aeovian Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aeovian Pharmaceuticals, Inc. engages in the development of pharmaceuticals. It offers inhibitors for the treatment of rare and age-related diseases. The company was founded by Stelios T. Tzannis in 2012 and is headquartered in Novato, CA. | Pharmaceuticals: Major | Director/Board Member | |
Palleon Pharmaceuticals, Inc.
 Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | Miscellaneous Commercial Services | Director/Board Member | |
Samsara Therapeutics, Inc.
 Samsara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Samsara Therapeutics, Inc. operates as a biopharmaceutical platform company. It engages in the development and commercialization of first-in-class therapeutics for the treatment of unmet medical needs and age-related diseases. The company was founded by Sebastian Aguiar in 2018 and is headquartered in Lewes, DE. | Pharmaceuticals: Major | Chief Executive Officer | |
| JANUX THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Medikine, Inc.
 Medikine, Inc. Pharmaceuticals: MajorHealth Technology Medikine, Inc. is a privately held biopharmaceutical company located in an undisclosed location. The American company's mission is to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a versatile drug discovery platform that generates modular "peptikines." These peptikines are peptide mimetics of cytokines that are smaller in molecular size than, and structurally unrelated to, the natural cytokines they emulate. Medikine's lead candidate, mdk-703, is currently in a phase 1 clinical trial in healthy volunteers. Ronald W. Barrett has been the CEO of the company since 2016. | Pharmaceuticals: Major | Chief Executive Officer | |
Cleara Biotech BV
 Cleara Biotech BV Pharmaceuticals: MajorHealth Technology Cleara Biotech BV operates as a biopharmaceutical company. It specializes in identification and specific elimination of subtypes of senescent cells with targeting age related diseases and counteracting therapy resistance in late stage cancer. The company was founded by Peter de Keizer, Marco Demaria, Tobias Madl and is headquartered in Utrecht, the Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
HAYA Therapeutics SA
 HAYA Therapeutics SA BiotechnologyHealth Technology HAYA Therapeutics SA is a Swiss precision medicines company that focuses on developing programmable therapeutics targeting regulatory RNAs derived from the dark genome to reprogram pathological cell states for a broad range of diseases, including cardiovascular disease and cancer. The company's discovery engine identifies novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA's lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting WISPER that is a heart-specific lncRNA known to be a fundamental regulator of pathological cardiac fibrosis in the context of heart failure. The company is headquartered at the Life Sciences Park Biopôle in Lausanne, CH, with laboratory facilities at JLABS @ San Diego. The company was founded by Samir Ounzain and Daniel Blessing, and Samir Ounzain has been the CEO since incorporation. | Biotechnology | Director/Board Member |
Statistiche
Distribuzione geografica
| Stati Uniti | 41 |
| Germania | 5 |
| Australia | 2 |
| Canada | 2 |
| Emirati Arabi Uniti | 2 |
Settori
| Health Technology | 26 |
| Consumer Services | 10 |
| Finance | 8 |
| Commercial Services | 6 |
| Retail Trade | 3 |
Posizioni
| Director/Board Member | 148 |
| Corporate Officer/Principal | 82 |
| Independent Dir/Board Member | 42 |
| Undergraduate Degree | 26 |
| Chairman | 23 |
Contatti più connessi
| Insiders | |
|---|---|
| Douglas Cole | 44 |
| John Freund | 37 |
| Meghan Fitzgerald | 28 |
| Helmut Schühsler | 28 |
| Jens Eckstein | 27 |
| Wendell Wierenga | 23 |
| Jesper Høiland | 12 |
| Jeffrey S. Williams | 11 |
| Nancy Stuart | 10 |
| Thomas G. Auchincloss | 9 |
| Christine van Heek | 9 |
| Ronald W. Barrett | 9 |
| Marc A. Becker | 9 |
| Ryan Daws | 9 |
| Kollol Pal | 8 |
- Borsa valori
- Insiders
- Ian Robert Silverman
- Connessioni Società
